R&D Looking ahead to 2026 in biopharma A look forward to trends to come in 2026, including AI-driven drug development, advanced modalities, and cardiometabolic disease therapies.
R&D Is this the year for precision psychology? With Amit Etkin At the Sachs Neuroscience Forum just before the start of JPM 2026 in San Francisco, pharmaphorum spoke with Amit Etkin, CEO of Alto Neuroscience.
R&D Sponsored Obesity, complexity, and the lab: What 2025 taught us, and w... The complexity of working with the patient population in obesity continues to challenge traditional trial design. hVIVO looks to the year ahead.
R&D A playbook for effective sponsor/CRO partnership Find out more about optimising sponsor/CRO collaboration in an interview on a case study in FI cell therapy.
R&D Shaping the future of immunodeficiency care, with Dr Jörg Sc... Dr Jörg Schüttrumpf, Chief Scientific Innovation Officer of Grifols, discusses advancing immunoglobulin (or IG) treatment for immune disorders.
R&D Closed & Collaborative H2 2025: Mergers, acquisitions, partn... The second half of 2025 showed pharma and healthcare leaning into partnerships that de‑risk innovation and compress time to market.
News ESMO26: Lily's sofe-m ADC stakes a claim in ovarian cancer Eli Lilly's first major readout at ESMO comes from a phase 1 trial of its FRα-targeting sofe-m in platinum-sensitive ovarian cancer (PSOC).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
